Venture-backed Solazyme Inc. has filed to raise $100 million in an initial public offering. Solazyme plans to list its shares on the Nasdaq Global Market under the symbol SZYM. The company’s backers include Lightspeed Venture Partners, The Roda Group, Harris and Harris Group, VantagePoint Venture Partners, Zygote Ventures, CTTV Investments LLC, the venture capital arm of Chevron Technology Ventures LLC, San-Ei Gen, Unilever, Bunge, Braemar Energy Ventures, and Sir Richard Branson via The Roda Group. Morgan Stanley and Goldman, Sachs & Co. are acting as lead underwriters.
On March 11, 2011, one of Keating Capital, Inc.’s portfolio companies, Solazyme, Inc., filed an S-1 registration statement to go public through a $100 million initial public offering of its common stock. Solazyme intends to list its shares on the Nasdaq Global Market under the symbol “SZYM.” Morgan Stanley and Goldman, Sachs & Co. are acting as lead underwriters.
Keating Capital made a $1 million investment in Solazyme in July 2010.
Solazyme is based in San Francisco, California, and is a leader in the development and commercialization of algal oil and bioproducts for the fuels and chemicals, nutrition, and skin and personal care markets.
About Keating Capital, Inc.
Keating Capital, Inc. (www.KeatingCapital.com) is a business development company that specializes in making pre-IPO investments in innovative, high growth private companies that are committed to and capable of becoming public. Keating Capital provides individual investors with the ability to participate in a unique fund that invests in a private company’s late stage, pre-IPO financing round — an opportunity that has historically been reserved for institutional investors.
Take your pick!
- Buyouts delivers exclusive news and analysis about private equity deals, fundraising, top-quartile managers and more. Get your FREE trial or subscribe now.
- VC Journal provides exclusive news and analysis about venture capital deals, fundraising, top-quartile investors and more. Get your FREE trial or subscribe now.